Metformin hydrochloride
GlucophageUpdated label
Previous label
With a related Warnings and Precautions addition.
excessive alcohol intake, hepatic impairment, and mitochondrial diseases to those risk factors. Warnings and Precautions now also state that metformin products are not recommended in patients with mitochondrial diseases such as MELAS syndrome and MIDD (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; maternally inherited diabetes and deafness).With a related Warnings and Precautions addition.
Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including duloxetine delayed-release capsule USP.Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including duloxetine delayed-release capsule USP.
No hyponatremia statement in this section.
The antidepressant-class suicidality boxed warning was unchanged.
screened for the presence of prostate cancer prior to treatment and at regular intervals afterwards.Patients should be screened for the presence of prostate cancer prior to treatment and at regular intervals afterwards.
No prostate-cancer screening statement.
Tamsulosin carries no boxed warning. The Intraoperative Floppy Iris Syndrome language on this label is longstanding and did not change this cycle.
Because zolpidem can cause drowsiness and a decreased level of consciousness, patients, particularly the elderly, are at higher risk of falls.In a clinical trial, 7% of pediatric patients treated with zolpidem 0.25 mg/kg taken at bedtime reported hallucinations versus 0% treated with placebo.No falls statement and no pediatric-hallucination figure in this section.
The complex-sleep-behavior boxed warning was unchanged.
Severe hypersensitivity reactions, including acute myocardial ischemia with or without myocardial infarction, and severe skin reactions such as toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), some with fatal outcome, have been reported.In case of such an anaphylactic or severe hypersensitivity reaction, discontinue treatment permanently and institute appropriate therapy.toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) — without a cardiac component.The Clostridioides difficile–associated-diarrhea boxed warning was unchanged.
Content removed from the boxed warning and relocated to Warnings.
Fixed drug eruption (FDE)… has been reported with carbamazepineFixed drug eruption (FDE)… has been reported with carbamazepine
Related change: Warnings and Precautions — New. This is a separate extended-release label.
Extended-release carbamazepine labelLabel updated: 2026-10-16
The use of promethazine hydrochloride injection by the following routes of administration is CONTRAINDICATED: Intravenous injection at concentrations greater than 1 mg/mL; Intra-arterial injection; Subcutaneous injection. The preferred route of administration is by deep intramuscular administration. Promethazine hydrochloride injection may be administered intravenously after dilution through an intravenous catheter inserted in a large vein. Preferably through a central venous catheter.If pain occurs at the injection site during intravenous infusion, immediately discontinue the infusion and evaluate for possible arterial injection or perivascular extravasation, and initiate appropriate medical management.Promethazine hydrochloride injection can cause severe chemical irritation and damage to tissues regardless of the route of administration… Adverse reactions include burning, pain, thrombophlebitis, tissue necrosis, and gangrene. In some cases, surgical intervention, including fasciotomy, skin graft, and/or amputation have been required… Due to the risks of intravenous injection, the preferred route of administration… is deep intramuscular injection. Subcutaneous injection is contraindicated.The Severe Tissue Injury, Including Gangrene portion was revised; the pediatric respiratory-depression portion was unchanged.
SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER.SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER.
all atomoxetine-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, and to consider stopping atomoxetine in patients who experience emergent suicidal thoughts and behavior.SUICIDAL IDEATION IN CHILDREN AND ADOLESCENTS.SUICIDAL IDEATION IN CHILDREN AND ADOLESCENTS.
Browse DailyMed human prescription label revisions with source comparisons and filters. Label publication dates refer to DailyMed publication.